Skip to main content
Erschienen in: Diabetologia 9/2009

01.09.2009 | Article

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

verfasst von: C. J. Currie, C. D. Poole, E. A. M. Gale

Erschienen in: Diabetologia | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The risk of developing a range of solid tumours is increased in type 2 diabetes, and may be influenced by glucose-lowering therapies. We examined the risk of development of solid tumours in relation to treatment with oral agents, human insulin and insulin analogues.

Methods

This was a retrospective cohort study of people treated in UK general practices. Those included in the analysis developed diabetes >40 years of age, and started treatment with oral agents or insulin after 2000. A total of 62,809 patients were divided into four groups according to whether they received monotherapy with metformin or sulfonylurea, combined therapy (metformin plus sulfonylurea), or insulin. Insulin users were grouped according to treatment with insulin glargine, long-acting human insulin, biphasic analogue and human biphasic insulin. The outcome measures were progression to any solid tumour, or cancer of the breast, colon, pancreas or prostate. Confounding factors were accounted for using Cox proportional hazards models.

Results

Metformin monotherapy carried the lowest risk of cancer. In comparison, the adjusted HR was 1.08 (95% CI 0.96–1.21) for metformin plus sulfonylurea, 1.36 (95% CI 1.19–1.54) for sulfonylurea monotherapy, and 1.42 (95% CI 1.27–1.60) for insulin-based regimens. Adding metformin to insulin reduced progression to cancer (HR 0.54, 95% CI 0.43–0.66). The risk for those on basal human insulin alone vs insulin glargine alone was 1.24 (95% CI 0.90–1.70). Compared with metformin, insulin therapy increased the risk of colorectal (HR 1.69, 95% CI 1.23–2.33) or pancreatic cancer (HR 4.63, 95% CI 2.64–8.10), but did not influence the risk of breast or prostate cancer. Sulfonylureas were associated with a similar pattern of risk as insulin.

Conclusions/interpretation

Those on insulin or insulin secretagogues were more likely to develop solid cancers than those on metformin, and combination with metformin abolished most of this excess risk. Metformin use was associated with lower risk of cancer of the colon or pancreas, but did not affect the risk of breast or prostate cancer. Use of insulin analogues was not associated with increased cancer risk as compared with human insulin.
Literatur
1.
Zurück zum Zitat Coughlin SS et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef Coughlin SS et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef
2.
Zurück zum Zitat Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 132:2208–2225PubMedCrossRef Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 132:2208–2225PubMedCrossRef
3.
Zurück zum Zitat Samami AA, Yakar S, LeRoith D, Brodt D (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47CrossRef Samami AA, Yakar S, LeRoith D, Brodt D (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47CrossRef
4.
Zurück zum Zitat Yang Y-X, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050PubMedCrossRef Yang Y-X, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050PubMedCrossRef
5.
Zurück zum Zitat Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305PubMedCrossRef Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305PubMedCrossRef
6.
Zurück zum Zitat Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef
7.
Zurück zum Zitat Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMedCrossRef Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMedCrossRef
8.
Zurück zum Zitat Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–441PubMedCrossRef Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–441PubMedCrossRef
9.
Zurück zum Zitat Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47:1071–1078PubMedCrossRef Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47:1071–1078PubMedCrossRef
10.
Zurück zum Zitat Gelfand JM, Margolis DJ, Dattani H (2005) The UK general practice research database. In: Strom BL (ed) Pharmacoepidemiology, 3rd edn. Wiley, Chichester, pp 337–346 Gelfand JM, Margolis DJ, Dattani H (2005) The UK general practice research database. In: Strom BL (ed) Pharmacoepidemiology, 3rd edn. Wiley, Chichester, pp 337–346
11.
Zurück zum Zitat Jick H, Jick SS (1991) Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 302:766–768PubMedCrossRef Jick H, Jick SS (1991) Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 302:766–768PubMedCrossRef
12.
Zurück zum Zitat Lewis JD, Shinnar R, Bilker W, Wang X, Strom BL (2007) Validation studies of the health improvement network for pharmacoepidemiology studies. Pharmacoepidemiol Drug Saf 16:393–401PubMedCrossRef Lewis JD, Shinnar R, Bilker W, Wang X, Strom BL (2007) Validation studies of the health improvement network for pharmacoepidemiology studies. Pharmacoepidemiol Drug Saf 16:393–401PubMedCrossRef
14.
Zurück zum Zitat Office for National Statistics (1996) The general practice research database: information for researchers. Office for National Statistics, London, pp 1–26 Office for National Statistics (1996) The general practice research database: information for researchers. Office for National Statistics, London, pp 1–26
15.
Zurück zum Zitat Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA (2006) Mortality in people with type 2 diabetes in the UK. Diabetic Med 23:516–521PubMedCrossRef Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA (2006) Mortality in people with type 2 diabetes in the UK. Diabetic Med 23:516–521PubMedCrossRef
16.
Zurück zum Zitat Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef
17.
Zurück zum Zitat Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef
18.
Zurück zum Zitat Eurich DT, McAlister FA, Blackburn DF et al (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335:497PubMedCrossRef Eurich DT, McAlister FA, Blackburn DF et al (2007) Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335:497PubMedCrossRef
19.
Zurück zum Zitat Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753–759PubMedCrossRef Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753–759PubMedCrossRef
20.
Zurück zum Zitat Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef
21.
Zurück zum Zitat Cazaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009) Is it time to test metformin in breast cancer trials? Cancer Epidemiol Biomarkers Prev 18:701–705CrossRef Cazaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009) Is it time to test metformin in breast cancer trials? Cancer Epidemiol Biomarkers Prev 18:701–705CrossRef
22.
Zurück zum Zitat Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA (2006) Genetics and biology of pancreatic cancer. Genes Dev 20:1218–1247PubMedCrossRef Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA (2006) Genetics and biology of pancreatic cancer. Genes Dev 20:1218–1247PubMedCrossRef
23.
Zurück zum Zitat Khaw K-T, Wareham N, Bingham S, Luben R, Welch A (2004) Preliminary communication: glycated hemoglobin, diabetes, and incidental colorectal cancer in men and women: a prospective analysis from the European Prospective Investigation into Cancer-Norfolk Study. Cancer Epidemiol Biomarkers Prev 13:915–919PubMed Khaw K-T, Wareham N, Bingham S, Luben R, Welch A (2004) Preliminary communication: glycated hemoglobin, diabetes, and incidental colorectal cancer in men and women: a prospective analysis from the European Prospective Investigation into Cancer-Norfolk Study. Cancer Epidemiol Biomarkers Prev 13:915–919PubMed
24.
Zurück zum Zitat Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes (UKPDS 80). N Engl J Med 359:1577–1589PubMedCrossRef Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes (UKPDS 80). N Engl J Med 359:1577–1589PubMedCrossRef
25.
Zurück zum Zitat Spencer EA, Pirie KL, Stevens RJ et al (2008) Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur J Epidemiol 23:793–799PubMedCrossRef Spencer EA, Pirie KL, Stevens RJ et al (2008) Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur J Epidemiol 23:793–799PubMedCrossRef
Metadaten
Titel
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
verfasst von
C. J. Currie
C. D. Poole
E. A. M. Gale
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 9/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1440-6

Weitere Artikel der Ausgabe 9/2009

Diabetologia 9/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.